AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06698367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation
Description: Protocol based on the best available evidence and to be used in all participants in both groups. The standard rehabilitation protocol will consist of three postoperative phases: Mobilization (0 to 4 weeks), Strengthening (4 to 8 weeks) and Functional phase (8 to 12 weeks). Sessions will be held 3 times a week for 12 weeks. Each session will last 1 hour and will consist of different modalities of therapeutic exercise and cryotherapy.
Study NCT06698367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Protocol based on the best available evidence and to be used in all participants in both groups. The standard rehabilitation protocol will consist of three postoperative phases: Mobilization (0 to 4 weeks), Strengthening (4 to 8 weeks) and Functional phase (8 to 12 weeks). Sessions will be held 3 times a week for 12 weeks. Each session will last 1 hour and will consist of different modalities of therapeutic exercise and cryotherapy.
Study NCT06698367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral high-intensity strength exercise
Description: Participants will be seated in an armchair with armrests and will perform 4 sets of 8 repetitions of an eccentric exercise for the pronosupinator muscles with a dumbbell with adjustable weights. The training will start with an intensity of 60% of 1RM, until reaching 80% 1RM.
Study NCT06698367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral mobility exercises
Description: Participants will be seated in an armchair with armrests and will perform 4 sets of 8 repetitions of an active mobility exercise for the pronation-supination muscles using a plastic rod.
Study NCT06700928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External focus training
Description: External focus training
Study NCT06700928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internal focus training
Description: internal focus training
Study NCT06700928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No attentional focus training
Description: no attentional focus training
Study NCT06703424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit-cycling
Description: Sit-cycling for 5 mins
Study NCT06703424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stand-twisting
Description: Stand-twisting for 5 mins
Study NCT06713096 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tempos Certos protocol
Description: Improve the enhanced recovery by using the Tempos Certos Protocol by the multiprofissional team , using interventions known by science and recommended by scientists.
Study NCT06711094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: Dalpiciclib: 125mg orally, with a treatment cycle every 28 days, with continuous administration for the first 3 weeks (days 1 to 21) and rest (no medication) for the second 1 week (days 22 to 28). It is recommended to take Dalpiciclib at about the same time every day.~Albumin-bound paclitaxel for injection: 125mg/m2, intravenous infusion for 30 minutes, D1, D8, every 28 days for a treatment cycle, at least ≥6 treatment courses.~Endocrine therapy: Endocrine therapy drugs are selected by the investigator
Study NCT06712511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine content
Description: Participants will drink the same volume of water or coffee, caffeine content is 2mg/kg by body weight.
Study NCT06711003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enhanced external counterpulsation
Description: Enhanced External Counterpulsation (EECP) is a non-invasive treatment primarily used for patients with angina or heart failure. It involves the application of pressure cuffs to the legs, which inflate and deflate in sync with the cardiac cycle. This enhances blood flow to the heart during diastole, the phase when the heart is resting between beats. The increased pressure promotes coronary artery perfusion, helping to improve oxygen delivery to the heart muscle, reduce angina symptoms, and enhance cardiovascular function. EECP is typically recommended for patients who are not good candidates for invasive procedures like angioplasty or bypass surgery, or for those seeking supplementary treatment for angina. Over time, it may promote the development of new blood vessels (collateral circulation), further improving heart health. The treatment is generally administered over several weeks in outpatient settings, with each session lasting around one hour.
Study NCT06711003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post acute care
Description: Post-Acute Care (PAC) for stroke patients focuses on improving functional independence, reducing disability, and preventing secondary complications.
Study NCT06711003 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: post acute care
Description: Post-Acute Care (PAC) for stroke patients focuses on improving functional independence, reducing disability, and preventing secondary complications.
Study NCT06714162 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Longevity pill
Description: vitamins and herbs
Study NCT06711341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole-body Vibration (WBV) Training
Description: Participants use the Compex Winplate, designed specifically for vibration training. The device is set with a frequency of 30 Hz and an amplitude of 4 mm. Participants perform a total of 5 exercises consisting of static and dynamic squat exercises, with a 30-second rest period between sets and between different exercises. The exercises and progression over the weeks are as follows:~Week 1:~* Static squat with knees flexed at 30° - 2 sets of 30 seconds each~* Dynamic squat with knees flexed between 0-60° - 2 sets of 30 seconds each~* Fingertip-to-sole partial dynamic squat with knees flexed at 30° - 2 sets of 30 seconds each~* Consecutive weight transfer with knees flexed at 45° - 2 sets of 30 seconds each~* Single leg static squat with knees flexed at 30° - 30 seconds per leg~Subsequent Weeks: The duration of each set increases by 10 seconds each week. Each training session includes a 5-minute warm-up and a 5-minute cooldown, consisting of joint motion and muscle stretching exercises.
Study NCT06711341 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Resistance Exercise (PRE)
Description: Training Duration: Participants undergo approximately 15-20 minute training sessions, 3 days per week for 3 weeks.~Exercise Regimen: The training focuses on strengthening the quadriceps muscles using ankle weights. The load is determined using the DeLorme principle:~* At the beginning of each week, the 10-repetition maximum (10RM) is measured.~* During that week, participants perform their training sets as follows:~  * First set: 50% of 10RM~ * Second set: 75% of 10RM~ * Final set: 100% of 10RM Each training session includes a 5-minute warm-up and a 5-minute cooldown, consisting of joint motion and muscle stretching exercises.
Study NCT06711341 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Exercise
Description: Protocol: Participants receive a printed document with instructions for home exercises and are instructed on how to perform the exercises.~Training Duration: Sessions are conducted three days per week for 3 weeks.~Exercise Regimen: The exercises include:~* Bilateral Quadriceps Isometric Exercise: Participants lie on their backs with a roll below each knee, pressing for 10-second holds, totaling 20 repetitions.~* Knee Extensions: Participants performed knee extensions while seated, holding each extension for 5 seconds, completing 10 repetitions per leg.~* Knee Range of Motion (ROM) Exercises: Participants lie face down and alternately bend their knees, completing 10 repetitions.~Each training session includes a 5-minute warm-up and a 5-minute cooldown, consisting of joint motion and muscle stretching exercises
Study NCT06714032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM plus conventional drug
Description: All patients were treated according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.
Study NCT06714032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCM placebo plus conventional drug
Description: All patients were treated according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.
Study NCT06714409 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VExUS guided decongestion
Description: Treatment team will be provided information about venous organ congestion status.
Study NCT06714097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI
Description: STRATIF-AI apps will be used as an integral part of the dialogue with patients during thesecondary prevention phase
Study NCT06714097 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: healthy dialogue
Description: Patients allocated to arm 2 will receive only standard secondary prevention, which includes typical treatments and monitoring protocols used for patients with stroke, Moyamoya disease, and CAA
Study NCT06713798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg IV
Description: atezolizumab (intravenous 1200mg Q3W)
Study NCT06713798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab 600 mg IV
Description: Tiragolumab (intravenous 600mg Q3W)
Study NCT06711172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health coaching intervention
Description: The health coaching intervention will consist of seventeen, 30 to 60-minute telehealth sessions that were dispersed over six months. Participants will work closely with a health coach to create a plan for making appropriate lifestyle changes and for accomplishing the clinical recommendations that were received from their comprehensive evaluation at the War Related Illness and Injury Study Center.
Study NCT05052983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Participants received either 1 \[30 milligram (mg)\] or 2 (2\*30 mg) subcutaneous (SC) injection(s) of nemolizumab every 4 weeks (Q4W) for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by interactive response technology (IRT).
Study NCT05052983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received either 1 (30 mg) or 2 (2\*30 mg) SC injection(s) of placebo every 4 weeks for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by IRT.
Study NCT06713395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The control group received standard postoperative care
Description: standard postoperative care
Study NCT06713395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PERMA
Description: 1. Establishment of the Integrated Psychological Intervention Team:~   The team consisted of 2 primary nurses, 4 specialist nurses, 1 psychologist, 2 physicians at the attending level or higher, and 2 researchers.~   Team Responsibilities: The primary and specialist nurses were responsible for implementing the intervention protocol. The physicians handled any adverse reactions experienced by the patients. The researchers were in charge of developing the intervention protocol and collecting data. All team members were required to undergo specialized training from the psychologist and pass an assessment before initiating the intervention.~2. Protocol Development:~   The intervention protocol, including specific content, team responsibilities, implementation process, and responses to adverse events, was carefully developed in written form by the researchers. The protocol was discussed and approved by all team members before implementation.~3. Protocol Implementation:~Emotional Support Intervention:
Study NCT06711796 — intervention group
Intervention type: DEVICE
Intervention: emg measurement in adductor pollucis
Description: EMG measurement from adductor pollucis and dorsal interosseus muscles in supination and pronation using increasing stimulation current
Study NCT06712979 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Lee Silverman Method
Description: Exercise protocol with 6 steps that the voice professionals adapted from Lee Silverman Method
Study NCT06712979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung volume recruitment technique - LVRT
Description: The adapted Lee Silverman Method will have a addiction of LVRT technique. Lung inflation begins, reaching an optimal inspiratory peak of 30 cmH2O. From this point, the sound /HA/ begins to be emitted until the most comfortable low sound, where the emission should be maintained for as long as possible, making sure that this time is not less than 12 seconds, trying to emit a high and comfortable vocal intensity. When performing the emissions, the mouth should be kept wide open with the tongue, jaw and neck relaxed, repeating 5 emissions in 3 series. Between series, the participant will be instructed to drink 50 ml of water exactly as in the previous emissions.
Study NCT06711263 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash Product
Description: * In the Initial Visit-Baseline, and subsequent visits, participants will be called in the morning. Morning hours will be chosen for examination, as it will reduce the risk of bias and also help in quantifying results. plaque and gingival scores will be recorded and the First herbal mouthwashes will be given, participants will also be provided new tooth-brushes (Oral B-soft).~* They will be asked to follow their routine oral hygiene habits. They will be asked to come back after 2 weeks for plaque and gingival bleeding scores recording for the second visit and again after 2weeks post the second visit for the third and final visit to record their plaque and gingival bleeding scores.
Study NCT06711263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash Product
Description: * In the Initial Visit-Baseline, and subsequent visits, participants will be called in the morning. Morning hours will be chosen for examination, as it will reduce the risk of bias and also help in quantifying results. plaque and gingival scores will be recorded and the First herbal mouthwashes will be given, participants will also be provided new tooth-brushes (Oral B-soft).~* They will be asked to follow their routine oral hygiene habits. They will be asked to come back after 2 weeks for plaque and gingival bleeding scores recording for the second visit and again after 2weeks post the second visit for the third and final visit to record their plaque and gingival bleeding scores.
Study NCT05866016 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skill birth attendant training
Description: It is an intervention targeted to enhance the competencies of Maternal Neonatal Health (MNH) service providers (skilled birth attendants) in Nepal. It is a capacity-building intervention that is expected to contribute to reducing maternal and neonatal morbidities and mortalities by improving the midwifery competencies (knowledge, attitudes, and skills) of MNH service providers.
Study NCT05866016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skill birth attendant training
Description: It is an intervention targeted to enhance the competencies of Maternal Neonatal Health (MNH) service providers (skilled birth attendants) in Nepal. It is a capacity-building intervention that is expected to contribute to reducing maternal and neonatal morbidities and mortalities by improving the midwifery competencies (knowledge, attitudes, and skills) of MNH service providers.
Study NCT06507657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin
Description: intake of a 10mg empagliflozin oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study.
Study NCT06507657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: intake a placebo oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study.
Study NCT05479045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 Peptide vaccine
Description: 300 mcg of NY-ESO-1 peptide, 100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant. The first two doses will be administered subcutaneously in a 2 week interval and thereafter, remaining three doses will be administered every 3 weeks.
Study NCT05479045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab-tpzi
Description: 240 milligrams (mg), intravenously, every 3 weeks starting with the second dose of NY-ESO-1 Peptide vaccine
Study NCT05763004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOS-1002
Description: monotherapy
Study NCT05763004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOS-1002 + KEYTRUDA® (pembrolizumab)
Description: combination therapy
Study NCT05681741 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: current versus high pump flow
Description: during each phase of randomized pump flow, arterial pressure will be increased from 40 to 90 mmHg with vasodilators and/or vasoconstrictors
Study NCT06492577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation protocol
Description: In the initial phase (days 1-7), aerobic exercise sessions will be 20-30 minutes, strength training will include 1-2 sets at 50% of 1RM, and breathing exercises will last 10 minutes daily. In the progressive phase (days 8-14), aerobic exercise sessions will increase to 30-40 minutes, strength training to 2-3 sets at 60% of 1RM, and breathing exercises to 10-15 minutes daily. In the advanced phase (days 15-21), aerobic exercise sessions will be 40-45 minutes, strength training will be 2-3 sets at 70% of 1RM, and breathing exercises will continue for 10-15 minutes daily.
Study NCT06492577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation protocol
Description: In the initial phase (days 1-7), aerobic exercise sessions will be 20-30 minutes, strength training will include 1-2 sets at 50% of 1RM, and breathing exercises will last 10 minutes daily. In the progressive phase (days 8-14), aerobic exercise sessions will increase to 30-40 minutes, strength training to 2-3 sets at 60% of 1RM, and breathing exercises to 10-15 minutes daily. In the advanced phase (days 15-21), aerobic exercise sessions will be 40-45 minutes, strength training will be 2-3 sets at 70% of 1RM, and breathing exercises will continue for 10-15 minutes daily.
Study NCT06492577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation protocol
Description: Participants in this arm will undergo a 21-day progressive muscle relaxation (PMR) program aimed at reducing anxiety and improving sleep quality in patients with long-term COVID-19 symptoms. Each daily session lasts 20 minutes and involves systematic muscle tensing and relaxation, starting from the feet and progressing to the head, combined with slow, deep breathing. During the initial phase (days 1-7), the focus is on introducing PMR techniques and targeting different muscle groups. In the progressive phase (days 8-14), full-body PMR sessions enhance relaxation and breathing techniques. The advanced phase (days 15-21) maximizes relaxation and incorporates visualization techniques.
Study NCT05629598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin injection
Description: The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).
Study NCT05629598 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human erythropoietin injection
Description: Refer to the product instructions
Study NCT06026189 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: urine-first strategy
Description: Only patients with an abnormal urine test result undergo a diagnostic workup, i.e. cystoscopy and upper-tract imaging.
Study NCT05394402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0410 Injection
Description: SHR0410 Injection
Study NCT05394402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SHR0410 Injection
Description: SHR0410 Injection blank preparation
Study NCT05512260 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Individual decision aid (iDA)
Description: A web-based iDA (accessible online with various content), will be developed towards individuals approached to cancer screening, although public and accessible to all who are interested in cancer and screening. DAs in screening usually include information on the disease, screening, screening tests, benefits and harms and some value clarification exercise (e.g., interactive questions) aiming at shedding light on the individual´s values and preferences, knowledge and lifestyle.
Study NCT04861740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autism ALERT
Description: Autism Access Link for Early Referral and Treatment \[ALERT\], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.